JP2024510762A5 - - Google Patents
Info
- Publication number
- JP2024510762A5 JP2024510762A5 JP2023557098A JP2023557098A JP2024510762A5 JP 2024510762 A5 JP2024510762 A5 JP 2024510762A5 JP 2023557098 A JP2023557098 A JP 2023557098A JP 2023557098 A JP2023557098 A JP 2023557098A JP 2024510762 A5 JP2024510762 A5 JP 2024510762A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridine
- imidazo
- ethoxy
- sinnoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/081254 | 2021-03-17 | ||
| PCT/CN2021/081254 WO2022193166A1 (en) | 2021-03-17 | 2021-03-17 | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
| PCT/CN2022/080905 WO2022194138A1 (en) | 2021-03-17 | 2022-03-15 | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510762A JP2024510762A (ja) | 2024-03-11 |
| JP2024510762A5 true JP2024510762A5 (cg-RX-API-DMAC10.html) | 2025-03-12 |
| JP7833477B2 JP7833477B2 (ja) | 2026-03-19 |
Family
ID=83321678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557098A Active JP7833477B2 (ja) | 2021-03-17 | 2022-03-15 | 血管拡張性失調症変異(atm)キナーゼの選択的モジュレーターおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240207263A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4308569A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7833477B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230157467A (cg-RX-API-DMAC10.html) |
| CN (1) | CN117412972A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021433713A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3213823A1 (cg-RX-API-DMAC10.html) |
| WO (2) | WO2022193166A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021433713A1 (en) * | 2021-03-17 | 2023-09-28 | Suzhou Zanrong Pharma Limited | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| JP5542832B2 (ja) | 2008-10-24 | 2014-07-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 生合成的に製造したピロリン−カルボキシ−リシンならびにピロリン−カルボキシ−リシンおよびピロリシン基の化学誘導体化を介する部位特異的タンパク質修飾 |
| NO2714752T3 (cg-RX-API-DMAC10.html) | 2014-05-08 | 2018-04-21 | ||
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| CN111344293A (zh) * | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
| WO2020052688A1 (en) * | 2018-09-14 | 2020-03-19 | Suzhou Zanrong Pharma Limited | 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF |
| AU2021433713A1 (en) * | 2021-03-17 | 2023-09-28 | Suzhou Zanrong Pharma Limited | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
-
2021
- 2021-03-17 AU AU2021433713A patent/AU2021433713A1/en active Pending
- 2021-03-17 WO PCT/CN2021/081254 patent/WO2022193166A1/en not_active Ceased
-
2022
- 2022-03-15 WO PCT/CN2022/080905 patent/WO2022194138A1/en not_active Ceased
- 2022-03-15 US US18/551,188 patent/US20240207263A1/en active Pending
- 2022-03-15 KR KR1020237035363A patent/KR20230157467A/ko active Pending
- 2022-03-15 CA CA3213823A patent/CA3213823A1/en active Pending
- 2022-03-15 CN CN202280035588.7A patent/CN117412972A/zh active Pending
- 2022-03-15 JP JP2023557098A patent/JP7833477B2/ja active Active
- 2022-03-15 EP EP22770491.3A patent/EP4308569A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7461390B2 (ja) | メニン-mll相互作用の阻害剤 | |
| CN112625028B (zh) | 用于抑制shp2活性的化合物和组合物 | |
| CN110325533B (zh) | Menin-mll相互作用的抑制剂 | |
| US11046699B2 (en) | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | |
| US10308660B2 (en) | Compounds and compositions for inhibiting the activity of SHP2 | |
| JP6242885B2 (ja) | 5−アザインダゾール化合物及び使用方法 | |
| AU2019381808A1 (en) | ERK inhibitors and uses thereof | |
| CA2984259A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| JP2023545274A (ja) | 癌を処置する化合物および方法 | |
| JP2011500806A5 (cg-RX-API-DMAC10.html) | ||
| US10526311B2 (en) | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | |
| TW200811159A (en) | Therapeutic compounds | |
| JPWO2021060453A5 (cg-RX-API-DMAC10.html) | ||
| JP2022500428A5 (cg-RX-API-DMAC10.html) | ||
| JP2013523814A5 (cg-RX-API-DMAC10.html) | ||
| JP2023505878A (ja) | インターフェロン遺伝子刺激因子(sting)のモジュレーターとしての複素環式化合物 | |
| TW202341982A (zh) | Cdk2抑制劑及其用途 | |
| JPWO2019216294A5 (cg-RX-API-DMAC10.html) | ||
| TW202525797A (zh) | 作為menin-mll交互作用之抑制劑的芳基醚類似物 | |
| WO2019197269A1 (en) | Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer | |
| JP2011522849A5 (cg-RX-API-DMAC10.html) | ||
| EP4301371A1 (en) | Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma | |
| TW202600142A (zh) | Her2抑制劑的劑量與治療方案 | |
| CN113563244A (zh) | 取代的氮杂五元环类化合物及其在药物中的应用 | |
| US20210369724A1 (en) | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |